RxDoctor Payments Data

Elizabeth Mole

Psychiatric/Mental Health · Pleasanton, CANPI 1376979237

Payments from drug & device makers

$4,185in general payments, 2019–2025

Across 197 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Alkermes, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$172
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$161
  • E.r. Squibb & Sons, L.L.C.$83
  • Neurocrine Biosciences, Inc.$26
  • plus $48 from 2 others

What the payments were for

  • Food & beverage$4,08898%
  • Education$972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,185 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.

See all psychiatric/mental health providers in California

Medicare billing

Part B allowed, 2024
$88,176
Medicare patients
139
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl32$67,483
PerserisRisperidone25$67,041
RexultiBrexpiprazole14$43,859
Abilify MaintenaAripiprazole14$36,491
TrintellixVortioxetine Hydrobromide26$33,576
Aripiprazole152$30,301
Lurasidone Hcl18$6,095
VyvanseLisdexamfetamine Dimesylate13$5,884
Olanzapine174$5,381
Wellbutrin SrBupropion Hcl13$4,149
Lisdexamfetamine Dimesylate19$3,874
Quetiapine Fumarate123$3,315
Quetiapine Fumarate ErQuetiapine Fumarate32$2,912
Ziprasidone Hcl40$2,766
Bupropion XlBupropion Hcl116$2,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$172$80,35028 claims
AbbVieVraylar$2,631$67,48332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.

Other psychiatric/mental health in Pleasanton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →